©2022 Stanford Medicine
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Trial ID: NCT01929408
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms
(MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:
- Present for an AML-like treatment that could plausibly produce a complete remission
(CR); for example intensive induction chemotherapy, low dose single agent
chemotherapy, hypomethylation agent, or a similar therapy
- Possibility to retrieve follow-up records from the collaborating institution or
treating primary care physician
- Patients with primary refractory or first relapse presenting for salvage chemotherapy
will be allowed
- Patients of 18 years of age or older, and are being treated by the adult AML service.
- Able to speak and read English.
- Willing and able to provide informed consent.
- Patients of ≤17 years of age or who are 18 or older and receive treatment under the
pediatric AML service.
- Patients older than 80 years
- Patients with <6 months projected survival due to active second malignancy or other
School of Medicine
300 Pasteur Drive
Stanford, CA 94305